Soo R.AAnderson B.OCho B.CCHIH-HSIN YANGLiao MLim W.-TGoldstraw PMok T.S.2020-05-262020-05-2620091470-2045https://www.scopus.com/inward/record.uri?eid=2-s2.0-71549117595&doi=10.1016%2fS1470-2045%2809%2970238-4&partnerID=40&md5=3f27c5324a4d558230a05409a73c3f6dhttps://scholars.lib.ntu.edu.tw/handle/123456789/495108Non-small-cell lung cancer (NSCLC) is an increasing global challenge, especially in low-income countries. Most guidelines for the management of advanced-stage NSCLC have limited effect in countries with resource constraints. Following a systematic literature search, we present an overview of the management of advanced-stage NSCLC in the first-line setting, discuss resources required for systemic therapy, and provide treatment recommendations stratified to four resources levels. Treatment guidelines appropriate for different resource levels offer a realistic approach to management of advanced-stage NSCLC, by recognising the limitations of a particular health-care system. Although there are many barriers to cancer control in low-resource countries, these can be overcome by using measures that are culturally appropriate, economically feasible, and evidence-based. Initiatives include strategic planning, tobacco control, training of health-care workers, access to therapeutic agents, acquisition of information, public education, and alliances with established institutions and international organisations. ? 2009 Elsevier Ltd. All rights reserved.[SDGs]SDG3bevacizumab; carboplatin; cetuximab; cisplatin; docetaxel; erlotinib; etoposide; gefitinib; gemcitabine; ifosfamide; irinotecan; mitomycin; navelbine; paclitaxel; pemetrexed; placebo; taxane derivative; teniposide; vinblastine; Vinca alkaloid; vindesine; advanced cancer; Asia; cancer survival; clinical trial; drug megadose; drug protein binding; drug response; elderly care; health care system; health program; human; low drug dose; lung non small cell cancer; maintenance therapy; multiple cycle treatment; nephrotoxicity; practice guideline; primary health care; priority journal; resource allocation; review; thrombocytopenia; treatment duration; vomiting; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; Carcinoma, Non-Small-Cell Lung; Congresses as Topic; Cost-Benefit Analysis; Developing Countries; Drug Costs; Evidence-Based Medicine; Guideline Adherence; Health Care Costs; Health Services Accessibility; Healthcare Disparities; Humans; Lung Neoplasms; Medical Oncology; Neoplasm Staging; Treatment OutcomeReview10.1016/S1470-2045(09)70238-4198800642-s2.0-71549117595